About this trial
This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Provide signed and dated informed consent form
Willing to comply with all study procedures and be available for the duration of the study
Male or female, aged >= 18
Life expectancy >= 3 months as assessed by Radiation Oncologist
Disqualifiers
Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
Palliative radiation doses defined as 20 Gy in 5 fractions
Trial design
Single group
Treatments tested in this trial
Fludeoxyglucose F-18
Other interventionGiven FDG
Positron Emission Tomography
Procedure/SurgeryUndergo PET-CT
Computed Tomography
Procedure/SurgeryUndergo PET-CT
Questionnaire Administration
Other interventionAncillary studies
Treatment groups
Trial outcomes
Primary outcomes
Change in mean standardized uptake value (SUV) changes in the heart
Measured by sarcoidosis fludeoxyglucose F-18 (FDG) positron emission tomography (PET)-computed tomography (CT) scans.
Secondary outcomes
Ability of pre- to post-radiotherapy SUV changes in the heart
Measured by sarcoidosis FDG PET-CT scans.
Overall survival
Survival
Cardiac toxicity
Assessed using \>= grade 2 and \>= grade cardiac events using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Cardiac toxicity judged to be secondary to radiotherapy by cardiologist and radiation oncologist
Judged to be secondary to radiotherapy by cardiologist and radiation oncologist
Sponsors and contacts
Click on the lead sponsor to view all of their trials.